These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 7724021)

  • 21. Acute effect of standard heparin versus low molecular weight heparin on oxidative stress and inflammation in hemodialysis patients.
    Poyrazoglu OK; Dogukan A; Yalniz M; Seckin D; Gunal AL
    Ren Fail; 2006; 28(8):723-7. PubMed ID: 17162433
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term effect of low molecular weight heparin on serum lipids in hypertriglyceridemic chronic hemodialysis patients.
    Vlassopoulos D; Noussias C; Hadjipetrou A; Arvanitis D; Logothetis E; Magana P; Katopodis K; Hadjiconstantinou V
    J Nephrol; 1997; 10(2):111-4. PubMed ID: 9238618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful control of postsurgical bleeding by recombinant factor VIIa in a renal failure patient given low molecular weight heparin and aspirin.
    Ng HJ; Koh LP; Lee LH
    Ann Hematol; 2003 Apr; 82(4):257-8. PubMed ID: 12707733
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Beneficial cardio-renovascular effects of a low-molecular-weight heparin-derivative on adriamycin-induced glycosaminoglycanuria and tissue lipid abnormalities.
    Deepa PR; Varalakshmi P
    Toxicology; 2005 Jul; 211(1-2):77-85. PubMed ID: 15863250
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in glucose tolerance, insulin, serum lipids and lipoproteins in patients with renal failure on intermittent haemodialysis.
    Arora KK; Atkinson MK; Trafford JA; Sheldon J; Nunn R
    Postgrad Med J; 1973 May; 49(571):293-6. PubMed ID: 4804451
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum lipid in chronic renal failure.
    Das BS; Misra SK; Rao DV; Satpathy SR; Bose TK
    J Assoc Physicians India; 1984 Dec; 32(12):1019-21. PubMed ID: 6526792
    [No Abstract]   [Full Text] [Related]  

  • 27. Levels of asymmetric dimethylarginine, nitric oxide and lipid peroxidation markers in patients with end-stage renal disease having peritoneal dialysis treatment.
    Göçmen AY; Sahin E; Koçak H; Tuncer M; Gümüşlü S
    Clin Biochem; 2008 Jul; 41(10-11):836-40. PubMed ID: 18457672
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum leptin, resistin, and lipid levels in patients with end stage renal failure with regard to dialysis modality.
    Taskapan MC; Taskapan H; Sahin I; Keskin L; Atmaca H; Ozyalin F
    Ren Fail; 2007; 29(2):147-54. PubMed ID: 17365928
    [TBL] [Abstract][Full Text] [Related]  

  • 29. About the effect of low-molecular-weight heparin on platelet function in haemodialysis patients.
    Eleftheriadis T; Antoniadi G; Liakopoulos V; Stefanidis I
    Nephrol Dial Transplant; 2009 Mar; 24(3):1063-4. PubMed ID: 19131348
    [No Abstract]   [Full Text] [Related]  

  • 30. Lipoperoxidation and hemodialysis.
    Ramos R; Martínez-Castelao A
    Metabolism; 2008 Oct; 57(10):1369-74. PubMed ID: 18803940
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low-molecular-weight heparins should be used with caution in patients with chronic kidney disease.
    Gallieni M; Cozzolino M; Ronga C; Brancaccio D
    Nat Clin Pract Nephrol; 2008 Sep; 4(9):488-9. PubMed ID: 18612327
    [No Abstract]   [Full Text] [Related]  

  • 32. [Anticoagulation in hemodialysis with a single dose of low molecular weight heparin].
    Vukusich A; Avalos C; Orellana G; Cifuentes C; Rivas J; Calderón F
    Rev Med Chil; 1995 Jun; 123(6):735-41. PubMed ID: 8525227
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Renal dyslipidemia in patients on chronic hemodialysis].
    Kovacić V; Sain M; Vukman V
    Lijec Vjesn; 2003; 125(3-4):77-80. PubMed ID: 12899098
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of various heparin preparations on lipoproteins in hemodialysis patients: a multicentre study.
    Kronenberg F; König P; Neyer U; Auinger M; Pribasnig A; Meisl T; Pinter G; Dieplinger H
    Thromb Haemost; 1995 Oct; 74(4):1025-8. PubMed ID: 8560405
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of unfractionated vs. low molecular weight heparin on tissue factor pathway inhibitor levels in hospital inpatients.
    Brown JR; Kuter DJ
    Thromb Haemost; 2001 Jun; 85(6):979-85. PubMed ID: 11434705
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The safety of heparins in end-stage renal disease.
    Sonawane S; Kasbekar N; Berns JS
    Semin Dial; 2006; 19(4):305-10. PubMed ID: 16893408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Long-term dialysis and its problems: abnormal lipid metabolism].
    Yasugi T; Shimizu T
    Nihon Rinsho; 1980 Jun; 38(6):2345-50. PubMed ID: 7411929
    [No Abstract]   [Full Text] [Related]  

  • 38. [Lipoprotein(a) and lipids in chronic renal insufficiency and kidney transplant].
    Ochoa-Sosa CA; Mondragón-Rodríguez G; Zamora-González J; Cardoso-Saldaña G; Herrera-Acosta J; Posadas-Romero C
    Rev Invest Clin; 1998; 50(4):301-6. PubMed ID: 9830317
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute effect of heparin on lipid parameters in patients on renal replacement therapy.
    Katopodis KP; Koliousi E; Gouva C; Balafa O; Bairaktari E; Ikonomou M; Elisaf MS; Siamopoulos KC
    ASAIO J; 2007; 53(1):46-9. PubMed ID: 17237649
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The association of lipid levels with mortality in patients on chronic peritoneal dialysis.
    Habib AN; Baird BC; Leypoldt JK; Cheung AK; Goldfarb-Rumyantzev AS
    Nephrol Dial Transplant; 2006 Oct; 21(10):2881-92. PubMed ID: 16735386
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.